Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 97

1.

VALIDATE: Exploiting the synergy between complex intracellular pathogens to expedite vaccine research and development for tuberculosis, leishmaniasis, melioidosis and leprosy.

Fletcher HA, Chatterjee M, Cooper A, Hussell T, Kaye PM, Prior J, Reljic R, Vermaak S, Vordermeier M, Williams A, McShane H.

F1000Res. 2018 Apr 23;7:485. doi: 10.12688/f1000research.14386.1. eCollection 2018.

2.

Tuberculosis.

Bloom BR, Atun R, Cohen T, Dye C, Fraser H, Gomez GB, Knight G, Murray M, Nardell E, Rubin E, Salomon J, Vassall A, Volchenkov G, White R, Wilson D, Yadav P.

In: Holmes KK, Bertozzi S, Bloom BR, Jha P, editors. Major Infectious Diseases. 3rd edition. Washington (DC): The International Bank for Reconstruction and Development / The World Bank; 2017 Nov 3. Chapter 11.

3.

[Frontier of mycobacterium research--host vs. mycobacterium].

Okada M, Shirakawa T.

Kekkaku. 2005 Sep;80(9):613-29. Japanese.

PMID:
16245793
4.

Development of Burkholderia mallei and pseudomallei vaccines.

Silva EB, Dow SW.

Front Cell Infect Microbiol. 2013 Mar 11;3:10. doi: 10.3389/fcimb.2013.00010. eCollection 2013. Review.

5.

[Recent progress in mycobacteriology].

Okada M, Kobayashi K.

Kekkaku. 2007 Oct;82(10):783-99. Japanese.

PMID:
18018602
6.

Integration of Metabolomics and Transcriptomics Reveals a Complex Diet of Mycobacterium tuberculosis during Early Macrophage Infection.

Zimmermann M, Kogadeeva M, Gengenbacher M, McEwen G, Mollenkopf HJ, Zamboni N, Kaufmann SHE, Sauer U.

mSystems. 2017 Aug 22;2(4). pii: e00057-17. doi: 10.1128/mSystems.00057-17. eCollection 2017 Jul-Aug.

7.

Host immune responses to mycobacterial antigens and their implications for the development of a vaccine to control tuberculosis.

Yuk JM, Jo EK.

Clin Exp Vaccine Res. 2014 Jul;3(2):155-67. doi: 10.7774/cevr.2014.3.2.155. Epub 2014 Jun 20. Review.

9.

[Development of antituberculous drugs: current status and future prospects].

Tomioka H, Namba K.

Kekkaku. 2006 Dec;81(12):753-74. Review. Japanese.

PMID:
17240921
10.

Correlates of immune protection following cutaneous immunization with an attenuated Burkholderia pseudomallei vaccine.

Silva EB, Goodyear A, Sutherland MD, Podnecky NL, Gonzalez-Juarrero M, Schweizer HP, Dow SW.

Infect Immun. 2013 Dec;81(12):4626-34. doi: 10.1128/IAI.00915-13. Epub 2013 Oct 7.

12.

Recombinant Salmonella Expressing Burkholderia mallei LPS O Antigen Provides Protection in a Murine Model of Melioidosis and Glanders.

Moustafa DA, Scarff JM, Garcia PP, Cassidy SK, DiGiandomenico A, Waag DM, Inzana TJ, Goldberg JB.

PLoS One. 2015 Jul 6;10(7):e0132032. doi: 10.1371/journal.pone.0132032. eCollection 2015.

13.

Immunization against leprosy: progress and prospects.

Noordeen SK, Sansarricq H.

Bull Pan Am Health Organ. 1984;18(3):295-99.

PMID:
6509251
14.

Functional Signatures of Human CD4 and CD8 T Cell Responses to Mycobacterium tuberculosis.

Prezzemolo T, Guggino G, La Manna MP, Di Liberto D, Dieli F, Caccamo N.

Front Immunol. 2014 Apr 22;5:180. doi: 10.3389/fimmu.2014.00180. eCollection 2014. Review.

15.

Melioidosis vaccines: a systematic review and appraisal of the potential to exploit biodefense vaccines for public health purposes.

Peacock SJ, Limmathurotsakul D, Lubell Y, Koh GC, White LJ, Day NP, Titball RW.

PLoS Negl Trop Dis. 2012 Jan;6(1):e1488. doi: 10.1371/journal.pntd.0001488. Epub 2012 Jan 31. Review. Erratum in: PLoS Negl Trop Dis. 2013 Feb;7(2). doi:10.1371/annotation/20664ec9-17e4-4ba6-8c65-481a70a5c4ad.

16.

[Novel vaccines against M. tuberculosis].

Okada M.

Kekkaku. 2006 Dec;81(12):745-51. Review. Japanese.

PMID:
17240920
18.

Differential interferon- gamma production characterizes the cytokine responses to Leishmania and Mycobacterium leprae antigens in concomitant mucocutaneous leishmaniasis and lepromatous leprosy.

Matos DS, Azeredo-Coutinho RB, Schubach A, Conceição-Silva F, Baptista C, Moreira JS, Mendonça SC.

Clin Infect Dis. 2005 Jan 15;40(2):e5-12. Epub 2004 Dec 22.

PMID:
15655736
19.

Immunogenicity of candidate chimeric DNA vaccine against tuberculosis and leishmaniasis.

Dey A, Kumar U, Sharma P, Singh S.

Vaccine. 2009 Aug 13;27(37):5152-60. doi: 10.1016/j.vaccine.2009.05.100. Epub 2009 Jun 24.

PMID:
19559111
20.

A naturally derived outer-membrane vesicle vaccine protects against lethal pulmonary Burkholderia pseudomallei infection.

Nieves W, Asakrah S, Qazi O, Brown KA, Kurtz J, Aucoin DP, McLachlan JB, Roy CJ, Morici LA.

Vaccine. 2011 Oct 26;29(46):8381-9. doi: 10.1016/j.vaccine.2011.08.058. Epub 2011 Aug 24.

Supplemental Content

Support Center